The Filing Desk

Kamada vs Syndax Pharmaceuticals

Kamada KMDA · Syndax Pharmaceuticals SNDX · Pharmaceuticals

Kamada reported revenue of $180 million in fiscal 2025, about the same as Syndax Pharmaceuticals' $172 million in fiscal 2025. Kamada's revenue grew 12.1% in its latest year, and Syndax Pharmaceuticals' grew 627.8%. Kamada had an operating margin of 14.5%, against -158.4% at Syndax Pharmaceuticals. Free cash flow was $16 million at Kamada and −$323 million at Syndax Pharmaceuticals.

Side by side

KamadaSyndax Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$180M$172M
Revenue growth12.1%627.8%
Revenue growth a year, last 5 years6.3%158.3%
Gross margin42.3%—
Operating margin14.5%−158.4%
Net margin11.2%−165.6%
Free cash flow$16M−$323M
Free cash flow margin8.7%−187.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$12M$0M
Change in diluted share count0.9%1.2%
Last close$7.83$9.13
P/E at the last close——
Insider trades, last 12 monthssold $1.7 millionsold $2.7 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
KamadaSyndax Pharmaceuticals
Operating margin
Percent of revenue
KamadaSyndax Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
KamadaSyndax Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kamada and Syndax Pharmaceuticals pages.